IP Library Granted Patent US 8,148,383
Granted Patent B2
US 8,148,383 · App. 12/696,147 · Granted Apr 3, 2012

Fused ring compound and use thereof

Assignee: Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,383
App. No.
12/696,147
Granted
Apr 3, 2012
Kind
B2
Abstract

Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.

Claims (4)

1. 6-{[3-Fluoro-2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-4-[trans-4-(2-hydroxy-1,2-dimethylpropoxy)cyclohexyl]-7-propyl[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one or a salt thereof.

2. A medicament comprising effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier.

3. (+)-6-{[3-Fluoro-2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-4-[trans-4-(2-hydroxy-1,2-dimethylpropoxy)cyclohexyl]-7-propyl[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one potassium salt.

4. A medicament comprising effective amount of the compound according to claim 3 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2010
From: MAEKAWA, TSUYOSHI; IGAWA, HIDEYUKI
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 024217/0473 →
Priority Claims (1)
JP 2009-020720 · Jan 30, 2009 · national
Continuity (1)
Related Publication 20100197683A1 · Aug 5, 2010